At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiplatelets; Piperazines; Piperidines; Small molecules; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary thrombosis; Thrombosis
Most Recent Events
- 18 May 1995 Discontinued-Preclinical for Coronary thrombosis in United Kingdom (Unknown route)
- 18 May 1995 Discontinued-Preclinical for Thrombosis in United Kingdom (Unknown route)
- 16 Jan 1995 Preclinical development for Coronary thrombosis in United Kingdom (Unknown route)